Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
An experimental glucagonlike peptide-1 (GLP-1) agonist, administered intranasally before meals, improves postmeal markers of glycemic control without severe adverse events in patients with type 2 diabetes, an exploratory trial finds.
Currently available agonists of GLP-1 are effective in treating type 2 diabetes but must be injected subcutaneously and can cause gastrointestinal adverse events. This experimental product, comprising a powder formulation of recombinant human GLP-1 (Asubio Pharma, Kobe, Japan) and a special intranasal injector device (SPG Technology, Miyazaki, Japan), might offer an alternative.
"Long-term treatment with this new nasal GLP-1 should be evaluated in larger trials to determine its safety, efficacy, and acceptability as a novel treatment for type 2 diabetes," say the authors, Hiroaki Ueno, MD, from the University of Miyazaki, Japan, and colleagues. Their results were published online March 25 in Diabetes Care.
http://www.medscape.com/viewarticle/823092
(free registration)
Currently available agonists of GLP-1 are effective in treating type 2 diabetes but must be injected subcutaneously and can cause gastrointestinal adverse events. This experimental product, comprising a powder formulation of recombinant human GLP-1 (Asubio Pharma, Kobe, Japan) and a special intranasal injector device (SPG Technology, Miyazaki, Japan), might offer an alternative.
"Long-term treatment with this new nasal GLP-1 should be evaluated in larger trials to determine its safety, efficacy, and acceptability as a novel treatment for type 2 diabetes," say the authors, Hiroaki Ueno, MD, from the University of Miyazaki, Japan, and colleagues. Their results were published online March 25 in Diabetes Care.
http://www.medscape.com/viewarticle/823092
(free registration)